Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC + DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTG

Clin Infect Dis. 2023 Apr 17;76(8):1492-1495. doi: 10.1093/cid/ciac949.

Abstract

Participants randomized to first-line tenofovir alafenamide (TAF)/emtricitabine (FTC)+dolutegravir (DTG), tenofovir disoproxil fumarate (TDF)/FTC + DTG, or TDF/FTC/efavirenz (EFV) for 192 weeks were then switched to TDF/lamivudine (3TC)/DTG for 52 weeks. Participants switching either TAF/FTC + DTG or TDF/FTC/EFV to TDF/3TC/DTG showed statistically significant reductions in weight, low-density lipoprotein, triglycerides, glucose and glycated hemoglobin.

Keywords: HIV; body weight; dolutegravir; efavirenz; tenofovir alafenamide.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenine / therapeutic use
  • Anti-HIV Agents* / therapeutic use
  • Benzoxazines / therapeutic use
  • Emtricitabine / therapeutic use
  • HIV Infections* / drug therapy
  • Humans
  • Lamivudine / therapeutic use
  • Tenofovir / therapeutic use

Substances

  • Lamivudine
  • Tenofovir
  • Emtricitabine
  • dolutegravir
  • efavirenz
  • Benzoxazines
  • Adenine
  • Anti-HIV Agents